In two pilot phase I studies, IDH1 inhibitor ivosidenib (118) achieved an ORR of 41.6%, and IDH2 inhibitor enasidenib (119) obtained an ORR of 40.3% in R/R AML patients with relevant mutations. The gene discussed is IDH2; the disease is acute myeloid leukemia.